BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26108332)

  • 21. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
    Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
    Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
    Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
    Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
    Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
    LaFave LM; Levine RL
    Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
    Chai J; Choudhuri J; Wang Q; Fang Y; Shi Y; Kamel J; Shah N; Sica RA; Kornblum N; Konopleva M; Mantzaris I; Shastri A; Gritsman K; Verma A; Goldfinger M; Goel S; Wang Y; Tian X
    Leuk Lymphoma; 2023 Oct; 64(10):1662-1672. PubMed ID: 37424335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility.
    Zhong Y; Wu J; Ma R; Cao H; Wang Z; Ding J; Cheng L; Feng J; Chen B
    Int J Lab Hematol; 2012 Jun; 34(3):248-53. PubMed ID: 22168550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
    Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST; Gotlib J
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
    Kearney L; Gonzalez De Castro D; Yeung J; Procter J; Horsley SW; Eguchi-Ishimae M; Bateman CM; Anderson K; Chaplin T; Young BD; Harrison CJ; Kempski H; So CW; Ford AM; Greaves M
    Blood; 2009 Jan; 113(3):646-8. PubMed ID: 18927438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
    Vainchenker W; Dusa A; Constantinescu SN
    Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
    Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
    Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia.
    Zhong Y; Chen B; Feng J; Cheng L; Li Y; Qian J; Ding J; Gao F; Xia G; Chen N; Lu Z
    Leuk Lymphoma; 2010 Jun; 51(6):1115-20. PubMed ID: 20536350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
    Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
    Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Two Novel Truncated Transcripts of Janus Kinase 2 Gene.
    Chang J; Chen X; Tian R; Xu Z; Tan Y; Guo H; Ren F; Xue F; Wang X; Yang W; Xu J; Wang H
    Ann Clin Lab Sci; 2020 Jul; 50(4):497-503. PubMed ID: 32826247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An insight into JAK-STAT signalling in dermatology.
    Palanivel JA; Macbeth AE; Chetty NC; Levell NJ
    Clin Exp Dermatol; 2014 Jun; 39(4):513-8. PubMed ID: 24825142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.